Tralokinumab for adolescents with moderate to severe atopic dermatitis

featured image
Indications: Atopic dermatitis
Therapeutic Areas: Dermatology
Year: 2020

Tralokinumab is proposed for the treatment of moderate to severe atopic dermatitis (AD) in adolescent patients (12-17 years old). AD is a chronic inflammatory skin disease that affects both children and adults and is characterised by redness, itchiness, and scaling of the skin. Some people only have small patches of dry skin, but others may experience widespread red, inflamed skin all over the body. Patients with moderate to severe AD could experience sleep disturbances, anxiety, depression, and poor quality of life. Currently, the management of AD involves the removal or treatment of trigger factors that contribute to the development of the disease.

Tralokinumab is a human monoclonal antibody that binds and neutralises the effect of the protein, interleukin 13 (IL-13), which plays a key role in triggering immune system responses in patients leading to AD. Tralokinumab is administered subcutaneously and is currently licenced for the treatment of adults. Evidence from clinical trials suggests an improvement in disease symptoms. If licensed, tralokinumab will offer an additional treatment option for adolescents with moderate to severe AD.